Intellia Therapeutics announced positive clinical results for lonvoguran ziclumeran (lonvo-z), a one-time CRISPR gene editing treatment for hereditary angioedema (HAE). In Phase 3 trials, lonvo-z reduced monthly attack rates by 81% compared to prior long-term prophylaxis, with 100% of patients becoming prophylaxis-free. The treatment showed durable efficacy and safety over up to four years, significantly improving patients' quality of life. Intellia plans a commercial launch pending FDA approval expected by March 2027.
Intellia Therapeutics' gene editing treatment lonvoguran ziclumeran (lonvo-z) is highlighted here for context. For readers following the Health sector, here is Pluang's market snapshot as of Nov 12, 2026 22:11 WIB: out of 150 priced US Health stocks, 42 rose and 108 fell. Among notable movers, BNGO traded at USD 1.02 with a 7.27% decline and a typical hold time of 52 days, while AXGN was priced at USD 54.92, down 6.33%, with a shorter hold time of 18 days and a strong buy order activity of 95%. NVAX stood at USD 9.36, down 6.26%, with a longer hold time of 60 days and predominantly sell orders at 83%.
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
atQor has been named a finalist for the 2026 Microsoft Partner of the Year Award in the Agents category, recognized for its innovative and scalable agentic AI solutions deployed across nine industries. The company developed 252 AI agents in FY26, wit...
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
